ReviewCancers2021
Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Neural Stem Cell-Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis.Journal of extracellular vesicles · 2026Article
- Extracellular vesicles in nipple discharge for breast cancer screening.Breast cancer research and treatment · 2026Article
- Article
- Review
- Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics.International journal of nanomedicine · 2026Review
- Advancing the potential of nanoparticles for cancer detection and precision therapeutics.Medical oncology (Northwood, London, England) · 2025Review
- Harnessing the power of stem cell-derived exosomes: a rejuvenating therapeutic for skin and regenerative medicine.3 Biotech · 2025Review
- Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles.Pharmaceutical research · 2024Review
- MiR-17-5p-engineered sEVs Encapsulated in GelMA Hydrogel Facilitated Diabetic Wound Healing by Targeting PTEN and p21.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Global trend in exosome isolation and application: an update concept in management of diseases.Molecular and cellular biochemistry · 2024Review
- Identification of key miRNAs and target genes in extracellular vesicles derived from low-intensity pulsed ultrasound-treated stem cells.Frontiers in genetics · 2024Article
- Extracellular Vesicles for Therapeutic Nucleic Acid Delivery: Loading Strategies and Challenges.International journal of molecular sciences · 2023Review
- Advances in Extracellular Vesicle Nanotechnology for Precision Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Application of Peptides in Construction of Nonviral Vectors for Gene Delivery.Nanomaterials (Basel, Switzerland) · 2022Review
- Transforming growth factor-β-induced secretion of extracellular vesicles from oral cancer cells evokes endothelial barrier instability via endothelial-mesenchymal transition.Inflammation and regeneration · 2022Article
- Chemically Modified Extracellular Vesicles and Applications in Radiolabeling and Drug Delivery.Pharmaceutics · 2022Review
- Extracellular vesicles: Targeting the heart.Frontiers in cardiovascular medicine · 2022Review
- Engineered small extracellular vesicles as a versatile platform to efficiently load ferulic acidFrontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Nucleic acid drugs, such as siRNAs, antisense oligonucleotides, and miRNAs, exert their therapeutic effects by causing genetic changes in cells. However, there are various limitations in their delivery to target organs and cells, making their application to cancer treatment difficult. Extracellular vesicles (EVs) are lipid bilayer particles that are released from most cells, are stable in the blood, and have low immunogenicity. Methods using EVs to deliver nucleic acid drugs to target organs are rapidly being developed that take advantage of these properties. There are two main methods for loading nucleic acid drugs into EVs. One is to genetically engineer the parent cell and load the target gene into the EV, and the other is to isolate EVs and then load them with the nucleic acid drug. Target organ delivery methods include passive targeting using the enhanced permeation and retention effect of EVs and active targeting in which EVs are modified with antibodies, peptides, or aptamers to enhance their accumulation in tumors. In this review, we summarize the advantages of EVs as a drug delivery system for nucleic acid drugs, the methods of loading nucleic acid drugs into EVs, and the targeting of EVs to target organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.